Your browser doesn't support javascript.
loading
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Spindler, K-L G; Andersen, R F; Jensen, L H; Ploen, J; Jakobsen, A.
Afiliação
  • Spindler KG; Department of Oncology, Danish Colorectal Cancer Group South, Vejle Hospital, Denmark. Electronic address: Karen-Lise.Garm.Spindler@slb.regionsyddanmark.dk.
  • Andersen RF; Department of Biochemistry, Danish Colorectal Cancer Group South, Vejle Hospital, Denmark.
  • Jensen LH; Department of Oncology, Danish Colorectal Cancer Group South, Vejle Hospital, Denmark.
  • Ploen J; Department of Oncology, Danish Colorectal Cancer Group South, Vejle Hospital, Denmark.
  • Jakobsen A; Department of Oncology, Danish Colorectal Cancer Group South, Vejle Hospital, Denmark.
Ann Oncol ; 21(3): 535-539, 2010 Mar.
Article em En | MEDLINE | ID: mdl-19850635

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Neoplasias Colorretais / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Fator de Crescimento Epidérmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2010 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Neoplasias Colorretais / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Fator de Crescimento Epidérmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2010 Tipo de documento: Article